NEW YORK, June 6-Nanogen said today that it will work with the U.S. Centers for Disease Control to adapt its chip-based system to detection of diarrheal Escherichia coli and other pathogens.
Nanogen will install one of its NanoChip workstations at the CDC's Foodborne and Diarrheal Diseases Branch in Atlanta, Ga. Under a "Development Site Agreement," CDC researchers will have preferential access to Nanogen technology as they develop assays for particular strains of pathogenic bacteria.
Nanogen receives licensing and commercialization rights to these assays, and may use this research to develop other diagnostic tests.
At the end of the program, the CDC will have an option to purchase the Nanogen system.
For more details, see the press release.